Heparin vs Lepirudin in Preventing Withdrawal Occulusion

肝素与来匹卢定在预防戒断性闭塞方面的比较

• 批准号: 7215838
• 负责人: mcdonald k horne
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7215838
• 关键词: cardiovascular disorder prevention; catheterization; chemoprevention; heparin; hirudins; human subject; human therapy evaluation; patient oriented research; vein occlusion

Central venous catheters are essential for the care of patients requiring chronic venous access, yet clots often develop at the catheter tip and block blood withdrawal. Although heparin flushes are routinely used to prevent this, their is little evidence that they are any more effective than saline. This study compares the effectiveness of standard heparin with flushes of a new anticoagulant, lepirudin, given at least daily for the first 3 - 4 weeks after the catheter has been inserted. The measured parameter is the frequency with which the catheters develop withdrawal occlusion. Fifty-one patients have been accrued on this study, which is about to be terminated because our essential research nurse has left our department and is not being replaced. The last patient accrued has just completed her period of observation. Once her chart is reviewed for incidences of catheter withdrawal occlusion, the study will be unblinded to determine whether it had sufficient power to demonstrate significant differences between the effect

中心静脉导管对于需要慢性静脉通路的患者的护理是必不可少的，但导管尖端往往会形成血栓，阻碍血液回流。尽管肝素冲洗剂经常用于预防这种情况，但几乎没有证据表明它们比生理盐水更有效。这项研究比较了标准肝素和新型抗凝剂来匹鲁丁的有效性，在导管插入后的头3-4周内，每天至少给药一次。测量的参数是导管发生退行性闭塞的频率。 这项研究已经积累了51名患者，该研究即将终止，因为我们的基本研究护士已经离开了我们的科室，不会被取代。最后一位患者刚刚结束了她的观察期。一旦检查了她的导管拔除阻塞的发生率，这项研究将不盲目地确定它是否有足够的能力来证明两种效果之间的显著差异